吉非替尼治疗晚期非小细胞肺癌疗效观察  

Treatment of non-small cell lung cancer with gefitinib

作　　者：张晓彤[1] 李龙芸[1] 王树兰[1] 穆新林[1] 王孟昭[1] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院呼吸内科,100730

出　　处：《中华结核和呼吸杂志》2005年第3期180-183,共4页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：目的探讨表皮生长因子酪氨酸激酶抑制剂-吉非替尼对晚期非小细胞肺癌(NSCLC)的治疗效果.方法对66例应用Iressa( 250 mg/d)治疗的晚期NSCLC患者生活质量、生存期等临床资料,采用Logistic回归分析、χ2检验、t检验的方法进行统计学分析.生活质量评估依据欧洲癌症研究和治疗组织 QLQ-C30 和 QLQ-LC13问卷中文版进行.结果本组患者用Iressa治疗的有效率为33%(22/66),疾病控制率(有效+稳定)为70%(46/66).患者生活质量及相关临床症状QLQ-C30评分中各功能状态和综合生活质量评分的均值显著增加,改善率为91%～100%;QLQ-LC13评分中各项疾病相关症状评分的均值显著降低,改善率为73%～100%.药物的不良反应主要为Ⅰ级或Ⅱ级皮疹和腹泻,经对症处理可缓解.结论吉非替尼用于晚期NSCLC治疗疗效确切,同时可改善患者的相关症状、提高生活质量.Objective To investigate the antitumor effects and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor gefitinib (Iressa) in advanced non-small cell lung cancer (NSCLC). Methods The clinical data and quality of life of 66 patients with NSCLC treated with Iressa orally at the dose of 250 mg/d were reviewed, and the data were analyzed by using logistic analysis, χ~2 test and t test. The impact of treatment on disease-related symptoms and quality of life was evaluated with Chinese version of European organization for research and treatment of cancer-quality of life core quanstionnair-30 (EORTC QLQ-C30)and QLQ-LC13. Results Tumor response rate was 33%. Disease control rate, which included both tumor responses and stable disease, was 70%. The mean scores of each functioning scales and global quality of life in QLQ-C30 increased significantly. Response rates were 91%-100%. Mean scores of disease-related symptoms decreased significantly. Response rates were 73%-100%. Quality of life and symptom response were correlated with objective tumour response. The 250 mg/day dose of Iressa was well tolerated by patients. The majority of adverse events were grade Ⅰ or grade Ⅱ skin rash and diarrhea, which were manageable and reversible. Conclusion Iressa offers a new treatment option providing meaningful tumor control and symptom relief for many patients with advanced NSCLC.

关 键 词：治疗 吉非替尼 患者 晚期非小细胞肺癌 生活质量 晚期NSCLC 疗效观察 评估依据 结论 综合 

分 类 号：R734.2[医药卫生—肿瘤] R735.7[医药卫生—临床医学]